Probiogen
ProBioGen AG is a Berlin-based biopharmaceutical CDMO founded in 1994 as a Charité spin-off. It provides proprietary cell line development, process development, and GMP manufacturing services for therapeutic proteins, antibodies, viral vectors, and vaccines to biotech and pharma clients worldwide.
- Company typePrivate
- Founded1994
- HeadquartersBerlin, Germany
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Probiogen does
ProBioGen AG is a Berlin-based Contract Development and Manufacturing Organization (CDMO) serving biotech and pharmaceutical clients globally. Founded in 1994 as a spin-off from Charité hospital and operating as a wholly-owned subsidiary of Egypt's Minapharm Pharmaceuticals since 2010, ProBioGen specializes in cell line development, process development, and GMP manufacturing of therapeutic proteins, antibodies, viral vectors, and vaccines. The company employs approximately 300 staff across three manufacturing sites in Berlin-Weißensee, operating two 1000L single-use bioreactor GMP protein lines as of 2025 with viral manufacturing capacity to 200L.
ProBioGen's offering is anchored by a portfolio of proprietary technology platforms: CHO.RiGHT (CHO DG44-based expression system), DirectedLuck (transposase system for stable cell line development), GlymaxX (ADCC enhancement through glycoengineering, with the first GlymaxX-modified product FDA-approved in 2024), AGE1.CR.pIX and AGE1.CR.ReX (avian designer cell lines for viral vaccine production), Lenti.RiGHT (lentiviral packaging and producer cell line), and MVA-CR19 (poxvirus vector platform). The CMC Navigator framework structures CDMO engagements into four service models (Sprint, Scale, Customize, Rise) covering the pathway from first-in-human studies through scalable production. The company holds more than 15 patent families and reports over 400 stable cell lines developed to date.
ProBioGen operates two revenue streams: contract development and manufacturing services billed per project, and outbound licensing of proprietary technologies (non-exclusive licenses include GlymaxX to Boehringer Ingelheim and AGE1.CR.pIX to Transgene and GeoVax Labs). The company sells to enterprise biotech and pharma clients through a direct business development team led by VP Business Development Dr. Michiel Stork and CBO Dr. Gabriele Schneider, supported by participation in major industry events including the J.P. Morgan Healthcare Conference and BIO International Convention. Management cites over 70% repeat business and named customers spanning Marea Therapeutics, Zag Bio, Spica Therapeutics, Nouscom, Chiome Bioscience, Polpharma Biologics, Ridgeline Discovery, ModeX Therapeutics, and Boehringer Ingelheim.
Probiogen firmographics
Firmographics- Name
- Probiogen
- Legal name
- ProBioGen AG
- Website
- https://probiogen.de
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- ProBioGen AG is a Berlin-based biopharmaceutical CDMO founded in 1994 as a Charité spin-off. It provides proprietary cell line development, process development, and GMP manufacturing services for therapeutic proteins, antibodies, viral vectors, and vaccines to biotech and pharma clients worldwide.
- Ownership category
- akta.pro rank
Probiogen industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Cell Therapy CDMO (HLAGABAD), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where Probiogen is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
Probiogen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services: Contract development and manufacturing services including cell line development, process development, GMP manufacturing, analytics, and bioassays for proteins, antibodies, viral vectors, and vaccines. Services offered as modular engagements from early development through commercial manufacturing.
- Technology Licensing: Licensing of proprietary technologies including AGE1.CR.pIX cell line, GlymaxX ADCC enhancement technology, CHO.RiGHT platform, and DirectedLuck transposase to other biopharma companies. Non-exclusive licenses granted to Boehringer Ingelheim (GlymaxX), GeoVax (AGE1.CR.pIX), and Transgene (AGE1.CR.pIX).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Probiogen product offering
Product offeringCore offering
ProBioGen AG is a Contract Development and Manufacturing Organization (CDMO) that provides cell line engineering, process development, and GMP manufacturing of biopharmaceuticals (proteins, antibodies, viral vectors, and vaccines) for biotech and pharma clients. The company augments its CDMO services with proprietary technology platforms (CHO.RiGHT, GlymaxX, DirectedLuck, AGE1.CR.pIX, AGE1.CR.ReX, Lenti.RiGHT, MVA-CR19) that enhance product quality, expression yields, and ADCC potency, and it also licenses these technologies to third parties.
Product overview
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of proprietary technologies and services for biopharmaceutical development. The core portfolio consists of: (1) Proprietary Technology Platforms including CHO.RiGHT® (protein expression), DirectedLuck® (transposase system), GlymaxX® (ADCC enhancement/glycoengineering), MVA-CR19 (vector platform), Lenti.RiGHT® (lentiviral production), and AGE1.CR.pIX®/AGE1.CR.ReX® (avian designer cell lines for viral vaccines); (2) A comprehensive suite of CDMO services spanning cell line development, process development (USP/DSP), GMP manufacturing, analytics, and regulatory support for proteins, antibodies, viral vectors, and vaccines; and (3) The CMC Navigator™ framework providing four structured service models (Sprint, Scale, Customize, Rise) for flexible client engagement. The company operates three manufacturing lines in Berlin with capacity up to 2000L, serving clients from early development through commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- CHO.RiGHT® Producer Cell Line Platform
Quantifiable outcome
- More than 70% of satisfied customers seen in repeat business
- +5 more outcomes
Companies that use Probiogen
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles4 records
Probiogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Probiogen partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- Zag BiocoreMaster Service Agreement for cell line development, process development, and GMP manufacturing for Zag Bio's ZAG-101 Fc-fusion autoimmune therapy targeting Type 1 diabetes. Clinical development targeted for late 2026. Zag Bio was founded in October 2024 and has secured $80 million including Series A financing.
- Spica TherapeuticsmajorCollaboration where ProBioGen performs GlymaxX-enhanced cell line development for Spica's clinical candidate ST101, an anti-CD163 antibody targeting tumor-associated macrophages. The partnership integrates ProBioGen's GlymaxX technology to enhance antibody ADCC activity.
- IAVIcoreMemorandum of Understanding with IAVI and Minapharm to develop and manufacture vaccines and biologics in Africa, focusing on Mpox and HIV. Initiative aims to strengthen local manufacturing and improve access to vaccines through technology transfers and collaborations with regional health organizations.
- Berlin Center for Gene and Cell Therapies (BC GCT)coreProBioGen to lead GMP manufacturing operations at the Berlin Center for Gene and Cell Therapies, a project led by Bayer AG, Charité, and Berlin Institute of Health. Represents major strategic expansion into cell therapy manufacturing.
- TransgenemajorLicense agreement for ProBioGen's AGE1.CR.pIX suspension cell line to support Transgene's individualized cancer vaccine program and myvac platform. Combines ProBioGen's production technology with Transgene's manufacturing capabilities.
- ModeX TherapeuticsminorProBioGen provided expertise for accelerated COVID-19 antibody development, including innovative cell engineering solutions.
- GeoVax LabsmajorMulti-product license for ProBioGen's AGE1.CR.pIX suspension cell line to bolster MVA-based vaccine development. GeoVax is a biotechnology company developing vaccines and immunotherapies.
- NouscommajorProBioGen's AGE1.CR.pIX production platform successfully used to manufacture viral vector product for Nouscom's clinical Phase II trial.
- Ridgeline Discovery (Versant Ventures)majorCDMO partnership for development of IgG1 antibody for autoimmune and cancer indications. Partnership demonstrated importance of collaboration and open communication in CDMO projects.
- Boehringer IngelheimmajorNon-exclusive license for ProBioGen's proprietary GlymaxX ADCC enhancement technology to produce antibodies with enhanced ADCC potency.
- Thermo Fisher ScientificmajorProBioGen engineered the Freedom CHO-S Kit platform in close collaboration with Thermo Fisher Scientific. The kit enables cost-and-time-efficient stable cell line development for research and commercial purposes and is available via Thermo Fisher Scientific.
- Polpharma BiologicsmajorAgreement for ProBioGen to provide high-performance cell line development services using CHO.RiGHT platform and proprietary technologies.
Scale indicators8 records
Recent moves12 records
Expansion highlights7 records
Probiogen competitors and assessment
Company assessmentOthers
Direct peers
- Rentschler Biopharma: German-headquartered, mid-sized CDMO focused on mammalian cell culture, process development and GMP manufacturing for therapeutic proteins and antibodies. Most direct strategic comparable — similar size, German quality positioning, biologics-only focus, and family/strategic ownership structure.
- Celonic: European biopharmaceutical CDMO offering cell line development, process development and GMP manufacturing for biologics, with new lentiviral vector capacity. Comparable service portfolio, similar size and German-speaking roots; new COO Dr. Simon Bulling joins ProBioGen from Celonic, signaling close competitive overlap.
- AGC Biologics: Global CDMO with mammalian and microbial biologics manufacturing plus viral vector (lentivirus, AAV) capabilities. Directly competes with ProBioGen across both protein and viral vector CDMO services, but at significantly larger scale.
- Oxford Biomedica: Specialist viral vector CDMO focused on lentiviral vectors for cell and gene therapy. Most relevant pure-play comparator for ProBioGen's Lenti.RiGHT and AAV services, though at a larger scale and listed.
Broad incumbents
- Boehringer Ingelheim BioXcellence: Global large-molecule CDMO inside a major pharma group, offering mammalian cell culture, viral vector and microbial services. Broader portfolio than ProBioGen and existing GlymaxX licensee, so it competes and partners simultaneously with the company.
- Cobra Biologics (Charles River Laboratories): Part of Charles River's CDMO segment, providing viral vector and plasmid DNA manufacturing. Directly comparable for ProBioGen's gene therapy CDMO offering, backed by a much larger parent.
- Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO with cell line development, process development and GMP manufacturing including viral vectors. Competes head-to-head on mammalian biologics with much larger commercial-scale capacity.
- Thermo Fisher Scientific (Patheon Biologics): Global CDMO via Patheon plus a major life-science tools vendor with whom ProBioGen co-developed the Freedom CHO-S Kit. Competes across biologics services while also serving as a strategic distribution and supply partner.
Regional players
- Minapharm Pharmaceuticals: Egyptian biopharmaceutical company and ProBioGen's parent since 2010. Owns large-scale commercial manufacturing capacity in Egypt/MENA that ProBioGen leverages for late-stage and commercial supply — a sibling/parent relationship rather than direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Probiogen social profiles
Digital presenceProbiogen compliance and trust
Trust signalCompliance1 record
Probiogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Probiogen leadership team
Management profileNumber of profiles
Profiles9 records
Probiogen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Probiogen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Probiogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Probiogen
What does Probiogen do?
ProBioGen AG is a Contract Development and Manufacturing Organization (CDMO) that provides cell line engineering, process development, and GMP manufacturing of biopharmaceuticals (proteins, antibodies, viral vectors, and vaccines) for biotech and pharma clients. The company augments its CDMO services with proprietary technology platforms (CHO.RiGHT, GlymaxX, DirectedLuck, AGE1.CR.pIX, AGE1.CR.ReX, Lenti.RiGHT, MVA-CR19) that enhance product quality, expression yields, and ADCC potency, and it also licenses these technologies to third parties.
Is Probiogen a public or private company?
Probiogen is a private company. It is classified as corporate owned and is currently operating.
When was Probiogen founded?
Probiogen was founded in 1994. It employs 251 to 500 people.
Where is Probiogen based?
Probiogen is headquartered in Berlin, Germany, in the Europe region.
How does Probiogen make money?
Two revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing.
Who are Probiogen's main competitors?
Lonza Biologics is listed as an others. Direct peers are Rentschler Biopharma, Celonic, AGC Biologics and Oxford Biomedica. Broad incumbents are Boehringer Ingelheim BioXcellence, Cobra Biologics (Charles River Laboratories), Fujifilm Diosynth Biotechnologies and Thermo Fisher Scientific (Patheon Biologics). Minapharm Pharmaceuticals is listed as a regional player.
Does Probiogen have an API?
No public API is recorded for Probiogen.
What industry is Probiogen in?
Probiogen's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.